| Literature DB >> 12049736 |
Ming Tan1, Tong Jing, Keng-Hsueh Lan, Christopher L Neal, Ping Li, Sangkyou Lee, Dexing Fang, Yoichi Nagata, Jiaxin Liu, Ralph Arlinghaus, Mien-Chie Hung, Dihua Yu.
Abstract
ErbB2 overexpression confers resistance to taxol-induced apoptosis by inhibiting p34(Cdc2) activation. One mechanism is via ErbB2-mediated upregulation of p21(Cip1), which inhibits Cdc2. Here, we report that the inhibitory phosphorylation on Cdc2 tyrosine (Y)15 (Cdc2-Y15-p) is elevated in ErbB2-overexpressing breast cancer cells and primary tumors. ErbB2 binds to and colocalizes with cyclin B-Cdc2 complexes and phosphorylates Cdc2-Y15. The ErbB2 kinase domain is sufficient to directly phosphorylate Cdc2-Y15. Increased Cdc2-Y15-p in ErbB2-overexpressing cells corresponds with delayed M phase entry. Expressing a nonphosphorylatable mutant of Cdc2 renders cells more sensitive to taxol-induced apoptosis. Thus, ErbB2 membrane RTK can confer resistance to taxol-induced apoptosis by directly phosphorylating Cdc2.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12049736 DOI: 10.1016/s1097-2765(02)00510-5
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970